Evaluation of Serum Ages Levels in Patients With Endometriosis

August 30, 2021 updated by: Pınar Yalcin bahat, Kanuni Sultan Suleyman Training and Research Hospital

The Serum Ages Levels in Patients With Endometriosis

Serum AGES (Advanced Glycation End Products) levels of endometriosis patients are compared with a group of healthy volunteers of the same age.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Serum AGES (Advanced Glycation End Products) levels are compared with 45 endometriosis patients and 45 healthy volunteers of the same age. The energy metabolism of the endometriosis group and its possible relationship with the endometriosis stage will be compared since AGES (Advanced Glycation End Products) gives information about the energy metabolism of the people.

Study Type

Observational

Enrollment (Actual)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • İ̇stanbul
      • Istanbul, İ̇stanbul, Turkey, 34000
        • Pinar Yalcin Bahat

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Women aged 18-45 diagnosed with endometriosis (surgery or ultrasound)

Description

Inclusion Criteria:

  • diagnosed with endometriosis (Surgery or ultrasound)
  • Women without endometriosis

Exclusion Criteria:

  • Women without endometriosis women who are only suspected endometriosis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
women with endometriosis
It consists of women between the ages of 18-45 who have been diagnosed with endometriosis by surgery or ultrasonography.
Other: Advanced Glycation End Products (AGEs)
Advanced Glycation End Products (AGEs) releated with energy metabolism, In this study, the possible relationship between the serum levels of Advanced Glycation End Products (AGEs) of endometriosis patients and the disease and its stage is evaluated.
control
It consists of healthy women between the ages of 18-45
Other: Advanced Glycation End Products (AGEs)
Advanced Glycation End Products (AGEs) releated with energy metabolism, In this study, the possible relationship between the serum levels of Advanced Glycation End Products (AGEs) of endometriosis patients and the disease and its stage is evaluated.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum Advanced Glycation End Products (AGEs) levels in women with endometriosis
Time Frame: 8 months
Serum Serum Advanced Glycation End Products (AGEs) levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group
8 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of the relationship between serum Serum Advanced Glycation End Products (AGEs) level and endometriosis stage
Time Frame: 8 months
By comparing the relation of serum Advanced Glycation End Products (AGEs) level with the stage of endometriosis, its relation with serum level in patients with advanced and early stage endometriosis will be examined. The possible effect of Advanced Glycation End Products (AGEs) on disease pathogenesis will be examined.
8 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kanuni Sultan Suleyman Training and Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

December 5, 2020

Primary Completion (ACTUAL)

July 20, 2021

Study Completion (ACTUAL)

July 30, 2021

Study Registration Dates

First Submitted

May 9, 2021

First Submitted That Met QC Criteria

May 9, 2021

First Posted (ACTUAL)

May 13, 2021

Study Record Updates

Last Update Posted (ACTUAL)

August 31, 2021

Last Update Submitted That Met QC Criteria

August 30, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • endo-serum ages levels

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endometriosis

Clinical Trials on Advanced Glycation End Products (AGEs)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe